Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC amplification + BCL2 amplification + TNFRSF8 expression
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2, TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
;
943
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MYC overexpression (18)
BCL2 overexpression (17)
TNFRSF8 positive (16)
TNFRSF8 expression (12)
MYC expression (9)
BCL2 expression (9)
BCL2 expression + MYC expression (8)
MYC overexpression + BCL2 overexpression (7)
BCL2 positive (7)
MYC positive (3)
MYC expression + BCL2 expression (2)
MYC underexpression (2)
miR-17-HG overexpression + MYC positive (2)
BCL2 overexpression + MCL1 overexpression (2)
BCL2 underexpression (2)
TNFRSF8 negative (2)
TNFRSF8 overexpression (2)
BCL2 overexpression + MYC overexpression (1)
BTK expression + BCL2 expression + MYC expression (1)
BTK expression + MYC expression (1)
CHEK1 overexpression + MYC overexpression (1)
MYC expression + BCL2 expression + BCL6 expression (1)
MYC expression + MCL1 expression (1)
MYC negative (1)
MYC positive + BCL2 positive (1)
MYC positive + BCL2 positive + BCL6 positive (1)
MYC expression + PAICS expression (1)
OTUD6B expression + MYC expression (1)
miR-17-HG expression + MYC positive (1)
BCL2 overexpression + CCND1 overexpression (1)
BCL2 overexpression + MCL1 expression (1)
BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression (1)
BCL2 positive + LGALS3 expression (1)
BTK expression + BCL2 expression (1)
CASP3 overexpression + BCL2 negative (1)
CASP3 underexpression + BCL2 positive (1)
CD20 expression + PAX5 expression + BCL2 expression (1)
CD22 underexpression + BCL2 overexpression (1)
CD20 expression + TNFRSF8 overexpression (1)
CD20 positive + MME positive + TNFRSF8 negative (1)
BCL2 positive + IGH positive (0)
MYC overexpression (18)
BCL2 overexpression (17)
TNFRSF8 positive (16)
TNFRSF8 expression (12)
MYC expression (9)
BCL2 expression (9)
BCL2 expression + MYC expression (8)
MYC overexpression + BCL2 overexpression (7)
BCL2 positive (7)
MYC positive (3)
MYC expression + BCL2 expression (2)
MYC underexpression (2)
miR-17-HG overexpression + MYC positive (2)
BCL2 overexpression + MCL1 overexpression (2)
BCL2 underexpression (2)
TNFRSF8 negative (2)
TNFRSF8 overexpression (2)
BCL2 overexpression + MYC overexpression (1)
BTK expression + BCL2 expression + MYC expression (1)
BTK expression + MYC expression (1)
CHEK1 overexpression + MYC overexpression (1)
MYC expression + BCL2 expression + BCL6 expression (1)
MYC expression + MCL1 expression (1)
MYC negative (1)
MYC positive + BCL2 positive (1)
MYC positive + BCL2 positive + BCL6 positive (1)
MYC expression + PAICS expression (1)
OTUD6B expression + MYC expression (1)
miR-17-HG expression + MYC positive (1)
BCL2 overexpression + CCND1 overexpression (1)
BCL2 overexpression + MCL1 expression (1)
BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression (1)
BCL2 positive + LGALS3 expression (1)
BTK expression + BCL2 expression (1)
CASP3 overexpression + BCL2 negative (1)
CASP3 underexpression + BCL2 positive (1)
CD20 expression + PAX5 expression + BCL2 expression (1)
CD22 underexpression + BCL2 overexpression (1)
CD20 expression + TNFRSF8 overexpression (1)
CD20 positive + MME positive + TNFRSF8 negative (1)
BCL2 positive + IGH positive (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC amplification + BCL2 amplification + TNFRSF8 expression
Diffuse Large B Cell Lymphoma
MYC amplification + BCL2 amplification + TNFRSF8 expression
Diffuse Large B Cell Lymphoma
brentuximab vedotin
Sensitive: C4 – Case Studies
brentuximab vedotin
Sensitive
:
C4
brentuximab vedotin
Sensitive: C4 – Case Studies
brentuximab vedotin
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.